Assessing safety of combining radiotherapy with new systemic therapies for breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety of administering concurrent radiotherapy alongside novel systemic therapies for breast cancer, including agents like capecitabine and HER2 inhibitors. It aims to determine whether these treatments can be safely synchronized or if one should be paused during the other. The research is motivated by previous findings suggesting a synergistic effect between certain molecular therapies and radiotherapy. The study will involve patients who require radiotherapy and are eligible for systemic therapy as per clinical guidelines.

Why it matters

Who can join: the full rules

Inclusion Criteria:

ECOG 0-2. Aged 18-70 years old. Pathologically diagnosed as breast cancer. Need to receive radiotherapy according to guidelines. Radiotherapy target volume included chest wall/breast with or without lymph node regions.

Need to receive one of the following therapies according to guidelines, capetabine, CDK4/6 inhibitor, PARP inhibitor , ICIs , HER2 inhibitors.

Exclusion Criteria:

Male breast cancer. Allergy to the upper medicines before. Will receive trastuzumab alone during and/or after radiotherapy. With severe other disease.

Where it's running

• Cancer Hospital ,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Yirui Zhai, MD — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Study coordinator: Yirui Zhai, MD
• Email: januarywind@163.com
• Phone: +86-10-87788058

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• PRaG-1 Plus PRaG Therapy with Radiation and Immunotherapy in Older Adults with Advanced Solid Tumors

  This study tests whether giving PRaG-1 Cordycepin tablets together with radiation, immune-boosting injections, and PD-1/PD-L1 inhibitors can help people aged 65 and older with advanced solid tumors.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07267234

• Lattice radiation combined with immunotherapy for advanced solid tumors

  This trial will test whether combining lattice (spatially fractionated) radiation with immunotherapy helps people with advanced or metastatic solid tumors.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07058948

• Multimodal radiotherapy for advanced renal cell carcinoma after immunotherapy

  This study is testing whether combining different types of radiation therapy with ongoing treatment can help people with advanced kidney cancer who haven't responded well to previous immunotherapy.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT06255223

• Induction chemotherapy with low-dose radiation and cadonilimab for locally advanced nasopharyngeal carcinoma

  This study will try adding low-dose radiation and the immune drug cadonilimab to induction chemotherapy before standard concurrent chemoradiotherapy in adults with newly diagnosed locally advanced nasopharyngeal carcinoma.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT05941741

• Combining advanced radiotherapy with immune therapy for lung cancer

  This study is testing a new treatment for advanced lung cancer that combines special radiation therapy with immune therapy to see if it can help patients feel better and improve their outcomes.

  Recruiting Xinqiao Hospital of Chongqing · Chongqing, Chongqing Municipality and 1 other locations · NCT05754203

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.